Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma
eJHaem · 2026-10 · 7 (5)
DOI: 10.1002/jha2.70388 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 21.09.2026. Verfasst von Ida Steiro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU) Trondheim…. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norges Teknisk-Naturvitenskapelige Universitet.
Abstract (Originalsprache)
Introduction
Bispecific antibody (BsAb) treatment can lead to increased infections in myeloma patients.
Methods
We used ELISpot and flow cytometry to test the T cell response to BCMA‐CD3‐bispecific T cell engager (BiTE) pavurutamab (PAV) and BCMA‐expressing myeloma cells after in vitro culture.
Results
Reduced pathogen‐specific responses were found in T cells cultured with PAV yet they killed myeloma cells. In an exploratory study, reduced pathogen‐specific memory T cell responses were detected in PBMCs from four myeloma patients responding to BCMA‐targeted BsAb therapy.
Conclusion
Our preliminary observation and its link to infection should be followed up in a larger study. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Autor:innen und Institutionen
- Department of Clinical and Molecular Medicine Faculty of Medicine and Health Sciences Norwegian University of Science and Technology (NTNU) Trondheim Norway.
- Oslo Myeloma Center Department of Hematology Oslo University Hospital Oslo Norway.
- KG Jebsen Center for B cell Malignancies Institute of Clinical Medicine University of Oslo Oslo Norway.
- Department of Hematology and Oncology Stavanger University Hospital Stavanger Norway.
- Institute of Clinical Medicine University of Oslo Oslo Norway.
- Department of Immunology and Transfusion Medicine St. Olav's Hospital - Trondheim University Hospital Trondheim Norway.
Förderung
- Norges Teknisk-Naturvitenskapelige Universitet
Zitieren
APA
Steiro, I., Tryggestad, S. S., Hess, E. S., Hella, H., Abdollahi, P., Moore, K. L. F., Friestad, M., Børset, M., Slørdahl, T. S., & Sponaas, A. M. (2026). Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma. eJHaem, 7(5). https://doi.org/10.1002/jha2.70388
Vancouver
Steiro I, Tryggestad SS, Hess ES, Hella H, Abdollahi P, Moore KLF, et al. Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma. eJHaem. 2026;7(5). doi:10.1002/jha2.70388
BibTeX
@article{Steiro2026,
author = {Steiro, Ida and Tryggestad, Synne Stokke and Hess, Eli Svorkdal and Hella, Hanne and Abdollahi, Pegah and Moore, Kari Lenita Falck and Friestad, Margrete and Børset, Magne and Slørdahl, Tobias S and Sponaas, Anne Marit},
title = {Reduced Pathogen‐Specific T Cell Response With BCMA‐Targeted T Cell‐Engaging Therapy to Multiple Myeloma},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {5},
doi = {10.1002/jha2.70388}
}
EUVIMED